Category: Pure Extracts Technologies

Posted on

PURE EXTRACTS SHIPS INITIAL VAPE CART ORDER TO BC LIQUOR DISTRIBUTION BRANCH

Vancouver, B.C., August 12, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped its initial order of one-gram, full spectrum oil (FSO) vape carts via its distribution partner to the British Columbia Liquor Distribution Branch (LDB).

As consumer preferences mature, demand for Pure Extracts’ Pure Pulls branded vape carts is high within the provincial markets as this product also offers exceptional value to the consumer while generating high margins for the Company. The cartridges were filled with a selection of some of the Company’s 30+ proprietary cannabis FSO formulations including Grand Daddy Purple and GSC.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited to have shipped our first order for one-gram FSO vape carts to the LDB for retail distribution to licensed dispensaries throughout our home province of British Columbia and we are proud to be a leading innovator in the cannabis vape sector. The combination of a larger form factor with our exceptional cannabis extracts will build on the loyal following Pure Pulls already has in place and continue to make the vape cart business a material revenue producer for Pure Extracts.”

These 510 vape cartridges are produced by a global manufacturer and adhere to the highest North American test standards. They were specifically chosen for the quality of their component parts, their fit and finish and their performance characteristics when paired with Pure Extracts’ oil concentrates.

Find out more about cannabis products available in B.C. at https://www.bccannabisstores.com/

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020 and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/. 

For more information:

Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

This news release contains forward-looking statements relating to the future operations of Pure Extracts,

and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

 

Posted on

PURE EXTRACTS SHIPS INITIAL EDIBLE CANNABIS GUMMIES ORDER TO BRITISH COLUMBIA

Vancouver, B.C., August 5, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped its initial order of edible cannabis gummies via its distribution partner to the British Columbia Liquor Distribution Branch (LDB).

Demand for the Company’s Pure Chews branded THC and CBD gummies is strong within the provincial markets. All the Company’s SKUs including the 10 mg THC packs of Fire Burst, Strawberry and Mango utilize a proprietary manufacturing system licensed from US based Taste-T, LLC, the manufacturer of the successful Fireball Cinnamon gummies, to produce and package branded cannabis gummies that come in unique blister packaging offering convenience and guaranteeing freshness. We anticipate that Fire Burst, like its US counterpart, will be one of the top selling gummies in the Canadian market.

“We are excited to have shipped our first order for Fire Burst cinnamon flavoured Pure Chews to the LDB, the wholesaler serving our home province of British Columbia,” said Ben Nikolaevsky, CEO. “The edible gummie business is a material revenue producer for Pure Extracts. With our proprietary manufacturing and packaging machine and our high-quality cannabis extracts, we have created the type of exceptional gummie products that consumers now demand.”

Find out more about cannabis products available in B.C. at https://www.bccannabisstores.com/

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020 and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

For more information:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com   

This news release contains forward-looking statements relating to the future operations of Pure Extracts,

and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

 

Posted on

PURE EXTRACTS RECEIVES SALES LICENCE FROM HEALTH CANADA

Vancouver, B.C., July 28, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has received approval from Health Canada to amend its license to permit the sale of cannabis extract products to provincially authorized distributors and retailers nationwide as well as to holders of licenses for the sale of medical cannabis extracts.

This approval is the result of an intensive review by Health Canada of Pure Extracts’ internal systems, processes, products and packaging. The Company’s purchase orders from British Columbia, Alberta, Saskatchewan and Ontario are currently being fulfilled by its distribution partner, thus having its own sales licence will allow Pure Extracts’ products to eventually reach all provincial and territorial jurisdictions across Canada without the help of an intermediary.

Pure Extracts’ CEO, Ben Nikolaevsky, remarked, “Our sales licence approval is the culmination of months of hard work and determination by our entire staff with their tireless concentration on quality and consistency. With sales of recreational products rising steadily as new Cannabis 2.0 products take hold in the marketplace, this approval paves the way for Pure Extracts to expand both our proprietary, in-house brands like Pure Pulls and Pure Chews as well as the other white label products that we are bringing to market.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

For more information:

Pure Extracts Investor Relations

Tel: +1 604 493 2052

info@pureextractscorp.com     

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

 

Posted on

PURE EXTRACTS SIGNS WHITE LABEL AGREEMENT WITH BRITISH COLUMBIA-BASED GREEN LIGHT SOLUTIONS

Vancouver, B.C., July 20, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has signed a custom manufacturing/white label agreement with Nelson, BC based Green Light Solutions Corp.’s (“GLS”) subsidiary, Joe’s Hemp Shack Inc., to launch a line of vape products.

The agreement calls for the initial extraction & formulation of premium hemp into high quality CBD vape cartridges. These products will be created by collaboration between the two companies with a reliance on Pure Extracts’ 30+ proprietary formulations and its optimized vape hardware. Pure Extracts will be providing co-manufacturing extraction services including all sales and distribution, labelling, packaging, applying of excise stamps and shipping.

GLS is an innovation firm committed to driving excellence in the Cannabis industry. GLS delivers value across multiple cannabis verticals through an agile, tech-forward business model, following cannabis and hemp specific strategies in its subsidiary business units. The company’s leadership team combines extensive experience in the cannabis industry with strong manufacturing and technology development expertise and a robust IP portfolio.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited about launching a white label product with our new partner, GLS, a fellow BC company, as they are focused on creating state-of-the-art cannabis-based products utilizing their small-batch cannabis and high-potency CBD hemp. With the addition of GLS and the increased capacity and flexibility our new cosolvent injection system provides, we have begun to execute our strategy with craft producers and branding specialists to get their white label products into the provincial dispensaries and drive up to $3 million of annual revenue from this vertical.”

Joe Corea, VP of Business Development at GLS, added, “Working with an experienced and agile manufacturing partner is critical in executing a differentiated product strategy. The emerging CBD market is dynamic, and by collaborating with adaptive partners, we can rapidly meet consumers’ evolving demands. We are confident that Pure Extract’s capabilities and market philosophy will enable us to disrupt the CBD vape category.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

For more information:

Pure Extracts Investor Relations

Tel: +1 604 493 2052

info@pureextractscorp.com    

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

Posted on

PURE EXTRACTS SIGNS PURCHASE ORDER WITH PRIVATE SASKATCHEWAN CANNABIS DISTRIBUTOR

Vancouver, B.C., July 15, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has signed a purchase order (PO) with a licensed cannabis distributor in the Province of Saskatchewan, further expanding the Company’s presence in Western Canada. Pure Extracts’ Pure Pulls cannabis vape cartridges and Pure Chews edible gummies will soon be available for purchase through select online outlets and private retailers in the province.

The PO calls for the initial purchase of .5 gram full spectrum oil (FSO) THC vape carts, THC/CBD blended vape carts, THC gummies as well as ultra-high potency CBD gummies. These products have been created by Pure Extracts from its IP consisting of 30+ proprietary formulations and all vape products have been optimized to perform flawlessly with the hardware chosen by the Company.

Pure Extracts’ CEO, Ben Nikolaevsky, remarked, “We are excited about launching our proprietary vape and edible brands in a third Western province. This marks another successful milestone in our country-wide rollout.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

For more information:

Pure Extracts Investor Relations

Tel: +1 604 493 2052

info@pureextractscorp.com    

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

 

Posted on

PURE EXTRACTS SUBMITS NATURAL HEALTH PRODUCT LICENCE APPLICATION FOR BLENDED FUNCTIONAL MUSHROOM PRODUCT

Vancouver, B.C., July 13, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly-owned subsidiary, Pure Mushrooms Corp., has submitted a licence application to Health Canada’s Natural and Non-Prescription Health Products Directorate for a blended functional mushroom wellness product.

This application for a blend of cordyceps, reishi and lion’s mane follows-up on the Company’s successful launch on its Amazon online e-Commerce store of sales of its reishi and maitake formulations. These 2 products are appealing to both men and women with 57% of purchases coming from men and 43% from women with the most sales occurring in California followed by Florida then Georgia.

The new blended formula provides antioxidants that help protect cells against the oxidative damage caused by free radicals. It is also used in Herbal Medicine as a liver tonic, to support the immune system and as an adaptogen to help increase energy and resistance to stress. Product launch is expected to occur in Q4 2021.

Pure Extracts’ CEO, Ben Nikolaevsky, remarked, “We are excited to be creating our next Pure Mushrooms’ products for our direct-to-consumer, online store. The functional mushroom wellness market is experiencing robust sales as many consumers are trying to boost their immune systems in light of the COVID-19 pandemic. As we build-out our mushroom extraction facility, we plan to bring more products to market.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

For more information:

Pure Extracts Investor Relations

Tel: +1 604 493 2052

info@pureextractscorp.com    

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

Posted on

PURE EXTRACTS PROVIDES CORPORATE UPDATE

Vancouver, B.C. (July 7, 2021) – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to provide a brief summary of recent activities.

Now that summer is here and the emergency health measures in Canada are moving towards a return to normalcy, we are enjoying continued business momentum and an increase in activity throughout every aspect of our enterprise operations. Recent events since our last update, combined with the ongoing positive energy we are experiencing led us to conclude a timely update would prove of interest to our growing base of partners, stakeholders and shareholders alike.

Market Awareness and Revenues

We are extremely pleased to advise that after an extensive period of regulatory adjustment, we have successfully achieved national consumer recognition for our Pure Pulls product brand at awareness levels better than what we experienced during the historically successful origins of the Company. With the onset of summer activities, less stringent health conditions and unleashing of pent-up demand for social and cultural events, we are confident that our expanded product lineup will quickly translate into increased visibility and sales. With revenues accruing as of our late spring commercial launch, the Company forecasts month-over-month growth as we continue to build momentum throughout the summer months and beyond.

Product Updates

Recent updates to our Pure Pulls product mix include production of innovative 1-gram, full spectrum oil (FSO), vape cartridges to meet a growing trend towards larger cartridges. These cartridges offer a selection of some of the Company’s 30+ proprietary cannabis FSO formulations including Super Lemon Haze, Grand Daddy Purple and GSC.

Pure Extracts timely strategic move into the edibles market has also led to several outstanding opportunities led by our Pure Chews brand lineup. This includes increased interest and visibility derived from our recent licensing agreement with U.S.-based Taste-T LLC, manufacturers of the Fireball gummie brand which is generally recognized on both sides of the border as the most visible brand in the sector. With the commissioning of the proprietary manufacturing equipment supplied by Taste-T LLC, including its innovative blister packaging, Pure Chews have a consistent manufacturing process offering superior product characteristics and scalable production efficiencies.

Supply Agreements

Canadian sales opportunities now include supply arrangements either in progress or nearing execution with provincially licensed outlets in Alberta, British Columbia, Saskatchewan and Ontario. Our transaction with a multi-state operator (MSO) in Michigan continues to move forward and we hope to have that closed over the next few weeks. We are excited about our expansion plans into the United States as Michigan is one of the largest per capita consumers of recreational cannabis in the United States. According to information both public and provided by regional stakeholders, Michigan had sales of over $180 million for cannabis and cannabis derived products in March 2021. Local competitors have publicly and regularly announced they have sold out of gummie and vape products which suggests that sales of our branded Pure Chews and Pure Pulls products could perform extremely well in this growing market where there are few if any current market leaders.

White Label Sales

Pure Extracts’ Canadian white label business continues to gain attention, interest and customers. The Company has already signed Flo Brands Inc. as a craft brand customer from BC along with a similar project for a large hemp producer also located in British Columbia. There are two additional brand operators in late-stage negotiations who have indicated they are currently out-of-contract and prepared to shift their product manufacturing from an existing Licensed Producer (LP) over to Pure Extracts. In the USA, our previously mentioned MSO partner in Michigan has indicated that along with co-locating Pure Extracts USA Inc. manufacturing equipment to produce Pure Pulls and Pure Chews products regionally, they would also become Pure Extracts USA Inc.’s first white label customer in America.

Functional Mushrooms and Online Sales

Pure Extracts has recently launched our products on the Abba Medix medical online website to generate sales from the medically regulated industry segment focussed on military veteran patients. Additionally, the functional mushrooms product sector continues to grow with the commencement of sales on Amazon USA. Amazon Canada sales are nearing commencement with sales on both sides of the border anticipated to be fully underway and on-target by Q4. Platform sales will see additional products coming online in Q3 with the addition of Lion’s Mane and a mushroom oil extract tincture product bringing the total number of retail SKU’s to 24, many of which are already available via retail outlets or as select offerings online.

Company CEO Ben Nikolaevsky notes, “Our business model is rapidly growing both in terms of revenue and through the advancement of product and partner development. Here in Canada, with over 75% of the eligible population having received at least one vaccination shot and caseloads dramatically decreasing, a sense of optimism is growing daily. Dispensary rollouts are ramping-up in the key Ontario market and our products are making their way to the shelves in 4 provinces. We have received some new equipment and there is more on the way that will subsequently make us one of the most efficient, lowest cost producers of cannabis extracts in North America. Our hard work and commitment to excellence were never a part of the problem over the past year and a half, and with the health restrictions receding we are now ideally positioned to unlock the value those efforts have created. We believe this is a breakout opportunity for our Company and hope we can personally meet many of our stakeholders, partners, and shareholders in the coming months to thank everyone for their exceptional assistance and faith in us. After all, although “Purity Starts Here” is a simple statement, it reminds us of exactly what we do. Thank you all.

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/.

For more information:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com    

Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding US expansion and the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

Posted on

JV Signed With Pure Extracts

Psyence Group and Pure Extracts sign JV letter of intent for the extraction of Psilocybin from psychedelic mushrooms and development of Psilocybin formulations.

Vancouver, B.C., March 31, 2021 (GLOBE NEWSWIRE) –Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.

Psyence is one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa and possessing an experienced global team of doctors and scientists striving for breakthroughs in palliative care, neurology, neuroscience and drug development.

Pure Extracts is a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector with a state-of-the-art processing facility and an application submitted to Health Canada for a Dealer’s Licence under the Controlled Drugs and Substances Act (CDSA). The companies plan to maximize the use of their combined infrastructure and networks in order to attain near-term milestones. Pure Extracts has a strong Canadian network of psychedelic mushroom experts, from cultivation to research & development, including Dr. Alexander MacGregor and his team at the Toronto Institute of Pharmaceutical Technology (TIPT), while Psyence’s network in South Africa, Lesotho and Jamaica has the expertise for the JV to rapidly develop natural psychedelics and novel drug delivery systems for patients throughout the world. Additionally, the Psyence team is experienced in structuring and running clinical trials and a near term goal will be to participate in a Canadian based, human clinical trial.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited about working with the deeply qualified science team at Psyence, one of only a handful of companies in the world operating a vertically integrated, federally licensed, psychedelic mushroom facility.” Dr. Justin Grant, Chief Scientific Officer of Psyence, commented, “This partnership with Pure Extracts will facilitate the importation of our standardized psychedelic mushrooms into Canada, giving us the opportunity to further optimize extraction methods and produce advanced products needed for safe clinical research. Our companies share the vision of providing the highest quality and most innovative psilocybin products for Canada, as evidenced by our facilities being constructed to GMP standards, and our commitment to rigorous scientific and clinical research for the development of transformational treatments for mental health disorders, with a particular focus on oncology palliative care.

About Psyence Group

The Psyence Group intends to set the global standard for natural psychedelics. Science-led by global experts in neurology, neuroscience and drug development, Psyence has built and operates one of the first federally licensed commercial psilocybin cultivation and production facilities. Psyence is pioneering the use of natural psilocybin for the long-term treatment of psychological trauma and its mental health consequences. Our global footprint operates across multiple legal jurisdictions, through the advanced provision of psychedelic therapy and experience, as well as market leading Functional Mushroom brands and product portfolio.

Psyence Contact Information

Lisa-Marie Iannitelli, Investor Relations
Email: ir@psyence.com
Media Inquiries: media@psyence.com
General Information: info@psyence.com

About Pure Extracts Technologies Corp

CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Website: https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively “the Company”) are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the approval of the Study and related activities by, and the obtaining of the requisite licences and consents from, the Jamaican regulatory and governmental authorities, the anticipation of the enactment or publication of regulation in the Jamaican psilocybin sector and the optimism surrounding the anticipated positive outcomes of the Study. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Posted on

Truffle Talk with Joshua Bartch of Mydecine Innovations Group

Published at Truffle Report

By Emily Jarvie

‍

Josh Bartch Mydecine

‍

  • Mydecine Innovations Group co-founder and CEO Joshua Bartch speaks to Truffle Report about the company’s psychedelics research program.
  • Mydecine’s lead program is focused on psilocybin and the treatment of post-traumatic stress disorder (PTSD).
  • Bartch says the company will be listed on three senior stock exchanges over the coming months.

At a time when he was looking for the next big industry, entrepreneur Joshua Bartch was attracted to the world of fungi by its unique compounds. “Diversification is incredibly important. With fungi, you can pursue oil remediation, break down plastic, and solve a lot of the world’s problems,” Bartch tells Truffle Report.

Along with geneticist Robert Roscow and hemp consultant Damon Michaels, Bartch co-founded biotechnology and life sciences company Mydecine Innovations Group to develop psychedelic-assisted therapies. “Our focus is the unique compounds that can promote health and wellness, and psychedelic compounds that can address unmet needs in the mental health arena,” Bartch says of the Colorado-based company.

Prior to becoming the CEO of Mydecine, Bartch had worked in the cannabis industry in Denver, Colorado starting in 2009. When recreational cannabis was legalized in the state in 2014, he launched Cannabase, a technology platform that connected standalone cultivators and retailers which was acquired 16 months later by Helix GCS. After selling significant professional and private cannabis-related assets, Bartch moved into mergers and acquisitions (M&A) and investing which ultimately led him to the psychedelics space.

Mydecine Conducting Clinical Trials on Psilocybin and PTSD

Bartch tells Truffle Report that Mydecine’s lead program is focused on the use of psilocybin and psilocybin-like compounds in conjunction with strict psychotherapy protocols for the treatment of post-traumatic stress disorder (PTSD), particularly among veteran populations. “In the United States alone, a veteran commits suicide every 72 minutes. That’s over 22 a day,” Bartch says.

“For whatever reasons, there’s been complacency with the current treatment models that maybe work half the time for half the population. Currently, there is not a single pharmaceutical drug that is manufactured for PTSD. Everything is borrowed, off-label, such as selective serotonin reuptake inhibitors (SSRIs) and Prozac which are incredibly dangerous drugs and are really ineffective for the treatment of PTSD because they carry side effects like suicide.”

Bartch says Mydecine has been working off a body of evidence from the 1950s and 60s which showed one to three macrodoses of psilocybin treatments, accompanied by strict psychotherapy protocols, had a success rate in excess of 75 percent in eliminating PTSD. “What is exciting for us is we are dealing with very ineffective band-aids that carry incredible negative side effects and we are able to replace it was a non-addictive, non-invasive treatment that has no known long-term side effects and can essentially act as a cure with one to three treatments combined with psychotherapy protocols,” he says.

Mydecine is ready to conduct Phase 2A clinical trials revolving around the use of psilocybin to treat PTSD, however, the trials have been put on hold due to COVID-19. “We have approved test sites at Leiden University in the Netherlands, the University of Western Ontario and the University of Alberta in Canada, and we are about to announce three very prominent veterans-focused sites in the United States,” Bartch says. He adds that the trial is expected to begin in the next few months once restrictions around COVID-19 allow it to proceed. “We don’t want to start the trial and then have to stop. To stop and restart could be very expensive and from a pure data standpoint is not the best,” he says.

Exclusive Partnership Sets Mydeceine Apart

Bartch says Mydecine’s exclusive access to a full cGMP pharmaceutical manufacturing facility at the University of Alberta was one way the company differentiated itself from others in the psychedelics space. “We have the ability to go from A to Z and turn a concept into reality,” Bartch tells Truffle Report. “Through the University of Alberta, which is covered by a Health Canada dealer’s licence, we have the ability to cultivate, extract, and isolate compounds which we can sell commercially. We can provide that active pharmaceutical ingredient (API) for our clinical trials to drastically lower the cost of our API or leverage our ability to produce these compounds, which can be used on humans, to participate in other studies we think are interesting or hold potential. To leverage that in exchange for shared data is advantageous.”

He adds that Mydecine supports the work of organizations exploring the medical potential of psychedelics in a responsible manner, such as through the passage of Measure 109 in Oregon. While Mydecine cannot take part in this state-based program itself, Bartch says the company supported the cause because it believes public acceptance of psychedelics is a significant barrier. “We don’t support the recreational use of psychedelics in any instance at all because we think it is a completely different substance to THC and it holds a higher medical potential to change the way mental health is being treated. Anything that is done responsibly that will better educate the public we think is a great thing for the industry,” he says.

Listing of Mydecine on Three Senior Stock Exchanges Underway

Mydecine is currently in the process of being listed on three senior stock exchanges: the NEO exchange in Canada, the London Securities Exchange (LSE) in the United Kingdom, and NASDAQ in the United States. The company is currently listed on the Canadian Securities Exchange (CSE) under the ticker symbol MYCO, on OTC Markets (OTC) in the United States under MYCOF, and on the Frankfurt Securities Exchange (FSE) under 0NFA.

Bartch tells Truffle Report he expects the first of the three new listings to be finalized will be the NEO exchange listing. “We believe that we will be trading on the NEO exchange within the next 30 days, around the first or second week of March,” he says. For the LSE, Bartch says Mydecine’s preliminary prospectus will be completed within the next few weeks. For the NASDAQ, Mydecine has been appointed a reviewer and Bartch says he expects the company will be listed in the next four to six months. “We continue to check boxes off,” Bartch says. “We have a couple of initiatives in the company that I can’t talk about now but the market should react accordingly and that should get us over the price requirement if not there could be additional capital raising to meet that requirement,” he says.

Being included in Horizons ETFs Managements’ first psychedelic stock ETF which began trading on the NEO Exchange in January is an honour, Bartch says. “The ETF was incredibly beneficial for the industry as a whole,” he says. “We would have been incredibly disappointed if we weren’t included because we feel we are an industry leader. As some of the initiatives we are working on come to light, we expect our percentage in the ETF will increase as we grow as a company.”

Posted on

16 healthcare professionals granted access to psilocybin

Canadian Government Agency Removes Barrier for Psilocybin Therapy

Health Canada removed a barrier for psilocybin research by allowing 16 health-care professionals to legally possess and consume psilocybin-containing mushrooms in clinical settings, the same exemptions previously given to more than a dozen terminally-ill patients. TheraPsil, a Victoria non-profit that aims to treat mental health issues with psilocybin, celebrates these exemptions, as they could lead to important new medical applications in the mental health sector.

PDF of article

DailyMushroom

|

© 2021 DAILY MUSHROOM. All Rights Reserved